Abstract:A major problem in the treatment of leukemia is the development of resistance to chemotherapeutic agents. There are several ways for cancer cells to develop resistance or defense mechanisms against cytotoxic drugs. This review paper will focus on membrane transport-associated multidrug resistance (MDR). The proteins involved, P-glycoprotein (P-gp), MRP1 and LRP/MVP, share the ability to act as drug transport proteins. Following upregulation of the mdr-1 gene, the energy-dependent transmembrane P-gp overexpression results in diminished intracellular concentrations of anthracyclins, vinca-alkaloids and epipodophyllotoxins. The other transmembrane protein, MRP1, also has intracellular epitopes which are involved in intracellular redistribution and sequestration of drugs. The last named mechanism has also been ascribed to LRP, a protein which only occurs intracellularly. In leukemia patients, cellular drug resistance profiles determined in vitro at the time of presentation show a strong correlation with outcome. In AML, mdr-1 overexpression at diagnosis is a strong independent predictor for CR and long-term survival. In ALL, mdr-1 expression is of minor importance for prediction of outcome. In AML, MRP1 expression at diagnosis is not correlated with clinical response and survival in most studies. In ALL, MRP1 expression at diagnosis is not associated with response and long-term survival in the few studies on this aspect which have been published. The studies on LRP in AML emphasize the importance of the correlation between LRP-expression and anthracycline accumulation and suggest that LRP-expression has prognostic value at diagnosis. However, there is an equal number of studies where a predictive value in the case of LRP-expression in de novo AML cannot be shown. The highest levels of LRP have been reported in multiple relapses of ALL. Furthermore, new membrane-associated drug transport proteins have been reported including the transporter associated with antigen processing (TAP), the anthracyclin resistance-associated protein (ARA), five new homologues of MRP (MRP2, or MOAT, MRP3, MRP4, MRP5, and MRP6), the sister of P-glycoprotein (sP-gp) and breast cancer resistance protein (BCRP). Studies on the (clinical) significance of these proteins have not yet been reported.

New Progress of Multidrug Resistance Studies in Leukemia

The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia

Recent Advances In P-Glycoprotein-Mediated Multidrug Resistance Reversal Mechanisms

Research and Clinical Significance of Relevant Signal Transduction Pathways Involved in P-glycoprotein-mediated Multidrug Resistance

Progress in the studies on the molecular mechanisms associated with multidrug resistance in cancers

Multidrug resistance-related proteins and their relationship with acute leukemia]

Recent advances in P-gp-mediated MDR reversal mechanisms

[Advances in the Study of Expression and Regulation of P-glycoprotein].

Comparison of Pgp- and MRP-Mediated Multidrug Resistance in Leukemia Cell Lines

Chemical molecular‐based approach to overcome multidrug resistance in cancer by targeting P‐glycoprotein (P‐gp)

Reversal of Multidrug Resistance by Magnetic Fe3o4 Nanoparticle Copolymerizating Daunorubicin and Mdr1 Shrna Expression Vector in Leukemia Cells

Insight on Multidrug Resistance and Nanomedicine Approaches to Overcome MDR

Strategies to overcome cancer multidrug resistance (MDR) through targeting P-glycoprotein (ABCB1): An updated review

Multidrug resistance inhibitors targeting P-glycoprotein

Recent Advances in the Research of P-glycoprotein Inhibitors.

Mechanism of multidrug resistance to chemotherapy mediated by P‑glycoprotein (Review)

Recent Advances in the Studies of Molecular Mechanisms Regulating Multidrug Resistance in Cancer Cells

Strategies to Overcome or Circumvent P-glycoprotein Mediated Multidrug Resistance.

The mechanisms of multidrug resistance of breast cancer and research progress on related reversal agents

Detection approaches for multidrug resistance genes of leukemia

Correlation between MDR1 genetic polymorphism and prognosis in acute leukemia